Controlling Oral Malodor by ClōSYS® Oral Rinse

Oral Malodor Clinical Trial

Official title:

Efficacy of ClōSYS® Oral Rinse Products in Human Subjects in Controlling Oral Malodor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03160560
• Other study ID #: LLUSD-RPR-Malodor-ADA-2016
• Status: Completed
• Phase: N/A
• Start date: August 2016
• Est. completion date: November 2016

Study information

• Verified date: December 2020
• Source: Rowpar Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this Study is to assess the efficacy of two ClōSYS Oral Rinse products in human subjects in controlling oral malodor in partial fulfillment of the requirements for American Dental Association's (ADA) requirement for obtaining ADA Seal for malodor.

Description:

Study Design:

The products used in the study are: ClōSYS Alcohol-Free Oral Rinse (also referred as ClōSYS Unflavored Oral Rinse) and ClōSYS justRIGHT MILD MINT Oral Rinse (also referred as ClōSYS Flavored Oral Rinse or Gentle Mint Flavored Oral Rinse). This is an in-vivo, eight-week, a single-center, randomized, double-blind (subject/investigator), 2-way cross-over design clinical study. There are two independent groups. Each subject of each group gets crossed over to the other sub-group within a same group after the washout period. Each group has their own control group. In the first phase, 25 subjects (50%) of each group are randomly assigned to the active group; the other 25 subjects are assigned to the control group. In the second phase, the participants will be crossed over within sub-group assignment. The Study enrolled 100 subjects, aged 21 to 65 years, with a slight to strong intrinsic oral malodor, as determined by a panel of trained odor judges calibrated and standardized using a range of standard odorants sufficient to reflect the different patterns of nose receptors.

Study Plan:

Subjects will receive verbal and written oral hygiene instructions, and either one bottle (16 oz. each) of ClōSYS Unflavored Oral Rinse, ClōSYS Flavored Oral Rinse- or Placebo Oral Rinse each week. Subjects will also receive measuring cups for dispensing the rinse and a diary log for recording usage (the Oral Hygiene Kit) for use during the treatment. After a 2-week wash out period, each subject will receive another bottle of oral rinse according to their group assignment.

Subjects will be instructed to rinse twice a day, each in the morning and in the evening, with 15 mL mouth rinse for 30 seconds. They will note in their patient's log the date and time of rinsing.

Subjects will be instructed to continue with their normal oral hygiene practices, including tooth brushing but omitting any use of oral rinses or mouthwashes except for the Study materials. The subjects also will be instructed not to use other non-study related products such as breath mints, lozenge, gums, etc. as well as refraining from elective dental procedures during the study period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• Completion of the Informed Consent.

• Must be able to follow verbal/written instructions.

• Between 21 to 65 years of age, male or female.

• Has normal oral interior cheek wall tissues.

• In good general health.

• Should not have any severe or debilitating disease that may impede participation.

• Average organoleptic intensity rating of at >2.6 but <4.5 on an intensity scale of 0-5.

Exclusion Criteria:

• Pregnant or nursing.

• Diagnosis of Xerostomia, including medication induced Xerostomia.

• Oral or extraoral piercing that interferes with the clinical assessments in the mouth.

• Fixed or removable oral appliance.

• Advanced periodontal disease or excessive gingival recession.

• Known allergy or sensitivity to study products.

• Unwilling to abstain from all oral hygiene products other than those prescribed for the study.

• Heavy deposits of calculus, either supragingival and/or subgingival.

• History of severe transmittable infectious disease e.g. hepatitis, HIV, tuberculosis.

• Medical or dental condition that would be unduly affected by participation in this study.

• Any other condition that may interfere with the study.

Related Conditions & MeSH terms

• Oral Malodor

Intervention

Drug:
• CloSYS® Unflavored Rinse
Subjects in Test group will receive CloSYS® Unflavored Rinse.
• CloSYS® Flavored Rinse
Subjects in Test group will receive CloSYS® Flavored Rinse.

Other:
• Placebo
Subjects in Placebo group will receive Placebo Rinse.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Rowpar Pharmaceuticals, Inc.	Loma Linda University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Malodor as Measured by Organoleptic Score	A 6-level organoleptic score from 0 - 5 will be used. Score of 0 indicating malodor cannot be detected and score of 5 indicating very strong malodor. Breath scores were compared to baseline with malodor intensity reduction recorded as negative.	At baseline and weekly for 3 weeks for each condition and cross-over